News Headlines

  1. Gan & Lee Partners With Lupin Limited To Accelerate Global Rollout Of Bofanglutide (GZR18) Biweekly GLP-1 RA 12/29/2025

    Gan & Lee Pharmaceuticals. (hereinafter "Gan & Lee" stock code: 603087.SH)announced that it had entered into an exclusive license and supply agreement with Lupin Limited (hereinafter "Lupin"), a leading pharmaceutical company headquartered in India, for its self-developed biweekly GLP-1 receptor agonist, Bofanglutide (Development code: GZR18).

  2. Adlai Nortye Enters Exclusive License Agreement With ASK Pharm For Pan-RAS (ON) Inhibitor AN9025 In Greater China 12/29/2025

    Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into an exclusive licensing agreement with ASK Pharm for its proprietary pan-RAS (ON) inhibitor AN9025.

  3. Oncodesign Precision Medicine And Navigo Proteins Announce The End Of Their Collaboration In The Development Of Radiotheranostics 12/29/2025

    Oncodesign Precision Medicine (OPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Navigo Proteins GmbH (Halle, Germany), a biopharmaceutical company specializing in the discovery and development of new precision medicine approaches based on the Affilin technology platform, jointly announce the termination of their collaboration agreement signed in May 2024.

  4. Transcenta Therapeutics Announces Strategic Collaboration And Non-Exclusive Licensing Agreement To Advance Integrated Continuous Biomanufacturing And Expand Global Access To Affordable Biologics 12/28/2025

    Transcenta Holding Limited (HKEX: 06628) (“Transcenta Therapeutics”), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced it has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. (“EirGenix”) (TWSE: 6589), a global biopharmaceutical development and manufacturing company.

  5. Harbour Biomed Enters Into Long-Term Strategic Collaboration With Lannacheng To Advance Next-Generation Radionuclide Drug Conjugates 12/28/2025

    Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology Co., Ltd.

  6. Zydus Partners With Bioeq For U.S. Commercialisation Rights For NUFYMCO®, An Interchangeable Biosimilar To Lucentis® 12/26/2025

    Bioeq AG ("Bioeq"), a Swiss biopharmaceutical company, and Zydus Lifesciences Limited ("Zydus"), an innovation-led life-sciences company with an international presence, today announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates has entered into a strategic partnership with Bioeq, for the licensing, supply and commercialization of Bioeq`s Vascular Endothelial Growth Factor (VEGF) inhibitor NUFYMCO®, an interchangeable biosimilar of Lucentis®1 (Ranibizumab) for the U.S. market.

  7. Italfarmaco And JCR Pharmaceuticals Announce Commercialisation Agreement For Givinostat In Japan And Strategic Collaboration In Rare Disease 12/24/2025

    Italfarmaco S.p.A.andJCR Pharmaceuticals Co., Ltd.(TSE 4552; “JCR”), today announced an exclusive licensing agreement for the development and commercialisation of givinostat in Japan.

  8. Akari Therapeutics Initiates GMP Manufacturing Of AKTX-101 ADC Program To Support Phase 1 First-In-Human Clinical Trial 12/23/2025

    Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, today announced the initiation of GMP manufacturing activities to support the development of AKTX-101, the Company’s lead ADC program.

  9. Samsung Biologics Expands U.S. Manufacturing Capabilities With Strategic Acquisition Of Human Genome Sciences From GSK 12/22/2025

    This strategic move secures Samsung Biologics’ first U.S.-based manufacturing site, a significant expansion of the company’s global footprint and its long-term commitment to the U.S. market.

  10. datma And Rhythm Biosciences Announce Collaboration To Apply Federated Real-World Data To Genomic Diagnostic Development 12/22/2025

    datma, a leader in federated real-world data access, and Rhythm Biosciences Ltd (ASX:RHY), a leading developer in predictive cancer diagnostics technology including its geneType™ risk assessment portfolio, today announced an exploratory collaboration to evaluate how datma.FED, datma's federated data platform, could support and accelerate the commercialization of Rhythm's genomic-integrated cancer risk prediction portfolio.